Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder

被引:0
|
作者
Zhang, Yuting
Adams, Alyce S. [1 ,2 ]
Ross-Degnan, Dennis [1 ,2 ]
Zhang, Fang [1 ,2 ]
Soumerai, Stephen B. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
基金
美国医疗保健研究与质量局;
关键词
ANGIOTENSIN-RECEPTOR BLOCKERS; STEP-THERAPY; PROGRAM; PHARMACOTHERAPY; SCHIZOPHRENIA; COMORBIDITY; 12-MONTH; DRUGS;
D O I
10.1176/ps.2009.60.4.520
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Few data exist on the cost and quality effects of increased use of prior-authorization policies to control psychoactive drug spending among persons with serious mental illness. This study examined the impact of a prior-authorization policy in Maine on second-generation antipsychotic and anticonvulsant utilization, discontinuations in therapy, and pharmacy costs among Medicaid beneficiaries with bipolar disorder. Methods: Using Medicaid and Medicare utilization data for 2001-2004, the authors identified 5,336 patients with bipolar disorder in Maine (study state) and 1,376 in New Hampshire (comparison state). With an interrupted time-series and comparison group design, longitudinal changes were measured in second-generation antipsychotic and anticonvulsant use; survival analysis was used to examine treatment discontinuations and rates of switching medications. Results: The prior-authorization policy resulted in an 8-percentage point reduction in the prevalence of use of nonpreferred second-generation antipsychotic and anticonvulsant medications (those requiring prior authorization) but did not increase use of preferred agents (no prior authorization) or rates of switching. The prior-authorization policy reduced total pharmacy reimbursements for bipolar disorder by $27 per patient during the eight-month policy period. However, the hazard rate of treatment discontinuation (all bipolar drugs) while the policy was in effect was 2.28 (95% confidence interval= 1.36-4.33) higher than during the prepolicy period, with adjustment for trends in the comparison state. Conclusions: The small reduction in pharmacy spending for bipolar treatment after the policy was implemented may have resulted from higher rates of medication discontinuation rather than switching. The findings indicate that the prior-authorization policy in Maine may have increased patient risk without appreciable cost savings to the state. (Psychiatric Services 60: 520-527, 2009)
引用
收藏
页码:520 / 527
页数:8
相关论文
共 50 条
  • [1] Economic and clinical impacts of prior authorization for antipsychotic and anticonvulsant medications among medicaid beneficiaries with bipolar disorder
    Zhang, Y.
    Adams, A. S.
    Ross-Degnan, D.
    Zhang, F.
    Soumerai, S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 : 293 - 294
  • [2] Medication Continuity Among Medicaid Beneficiaries With Schizophrenia and Bipolar Disorder
    Brown, Jonathan D.
    Barrett, Allison
    Caffery, Emily
    Hourihan, Kerianne
    Ireys, Henry T.
    PSYCHIATRIC SERVICES, 2013, 64 (09) : 878 - 885
  • [3] Medicaid Prior Authorization and Opioid Medication Abuse and Overdose
    Cochran, Gerald
    Gordon, Adam J.
    Gellad, Walid F.
    Chang, Chung-Chou H.
    Lo-Ciganic, Wei-Hsuan
    Lobo, Carroline
    Cole, Evan
    Frazier, Winfred
    Zheng, Ping
    Kelley, David
    Donohue, Julie M.
    AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (05):
  • [4] EFFECT OF ATYPICAL ANTIPSYCHOTIC PRIOR AUTHORIZATION IMPLEMENTATION ON PATIENT OUTCOMES AMONG OHIO MEDICAID BENEFICIARIES
    Thompson, J. A.
    Kelton, C. M.
    Lin, A. C.
    Winstanley, E. L.
    Heaton, P. C.
    VALUE IN HEALTH, 2017, 20 (05) : A303 - A304
  • [5] Association Between Prior Authorization for Medications and Health Service Use by Medicaid Patients With Bipolar Disorder
    Lu, Christine Y.
    Adams, Alyce S.
    Ross-Degnan, Dennis
    Zhang, Fang
    Zhang, Yuting
    Salzman, Carl
    Soumerai, Stephen B.
    PSYCHIATRIC SERVICES, 2011, 62 (02) : 186 - 193
  • [6] Prior Authorization for Antidepressants in Medicaid Effects Among Disabled Dual Enrollees
    Adams, Alyce S.
    Zhang, Fang
    LeCates, Robert F.
    Graves, Amy Johnson
    Ross-Degnan, Dennis
    Gilden, Daniel
    McLaughlin, Thomas J.
    Lu, Christine
    Trinacty, Connie M.
    Soumerai, Stephen B.
    ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (08) : 750 - 756
  • [7] Discontinuities in atypical antipsychotic therapy following prior authorization and step therapy among medicaid beneficiaries with schizophrenia
    Soumerai, S. B.
    Zhang, F.
    Ross-Degnan, D.
    Ball, D. E.
    Lecates, R. F.
    Law, M. R.
    Hughes, T. E.
    Chapman, D.
    Adams, A. S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 : 64 - 65
  • [8] Effects of a Medicaid Prior Authorization Policy for Pregabalin
    Margolis, Jay M.
    Johnston, Stephen S.
    Chu, Bong-Chul
    Onukwugha, Eberechukwu
    Hvidsten, Kyle
    Alvir, Jose
    Rossi, Joseph G.
    Mullins, C. Daniel
    AMERICAN JOURNAL OF MANAGED CARE, 2009, 15 (10): : E95 - E102
  • [9] Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) Scale to Assess the Effects of Prior Authorization Among Texas Medicaid Providers
    Brown, Carolyn M.
    Nwokeji, Esmond
    Rascati, Karen L.
    Zachry, Woodie
    Phillips, Glenn A.
    ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH, 2009, 36 (04) : 278 - 287
  • [10] Development of the Burden of Prior Authorization of Psychotherapeutics (BoPAP) Scale to Assess the Effects of Prior Authorization Among Texas Medicaid Providers
    Carolyn M. Brown
    Esmond Nwokeji
    Karen L. Rascati
    Woodie Zachry
    Glenn A. Phillips
    Administration and Policy in Mental Health and Mental Health Services Research, 2009, 36 : 278 - 287